Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.81 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.81 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.59 |
| ▸ | JAK3 | P52333 | 2/20 | 0.59 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868800 | 0.90 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL868801 | 0.90 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL16681478 | 0.84 | EGFR (0.79) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL15391293 | 0.84 | EGFR (0.79) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL10108150 | 0.83 | EGFR (0.80) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL867824 | 0.81 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL867825 | 0.81 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL1418284 | 0.79 | EGFR (0.81) | EGFRERBB2 | |
| SCHEMBL1418278 | 0.79 | EGFR (0.81) | EGFRERBB2 | |
| SCHEMBL7914891 | 0.79 | FYN (0.78) | EGFRERBB2ERBB4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | EGFR 48/4885ERBB2 7/4885ERBB4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.